Shigella in Africa: New Insights From the Vaccine Impact on Diarrhea in Africa (VIDA) Study
Clinical Infectious Diseases · 19.04.2023 · 76 (Supplement_1) · S66-S76
DOI: 10.1093/cid/ciac969 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 19.04.2023. Verfasst von Irene N Kasumba und 28 weiteren Autor:innen. Beteiligte Einrichtung: Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland. Hauptthemen laut MEDLINE: Dysentery, Bacillary, Shigella. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bill & Melinda Gates Foundation.
Abstract (Originalsprache)
Background
We evaluated the burden of Shigella spp from children aged 0–59 months with medically attended moderate-to-severe diarrhea and matched controls at sites in Mali, The Gambia, and Kenya participating in the Vaccine Impact on Diarrhea in Africa (VIDA) study from 2015 to 2018.
Methods
Shigella spp were identified using coprocultures and serotyping in addition to quantitative polymerase chain reaction (qPCR). Episode-specific attributable fractions (AFe) for Shigella were calculated using Shigella DNA quantity; cases with AFe ≥0.5 were considered to have shigellosis.
Results
The prevalence of Shigella was determined to be 359 of 4840 (7.4%) cases and 83 of 6213 (1.3%) controls by culture, and 1641 of 4836 (33.9%) cases and 1084 of 4846 (22.4%) controls by qPCR (cycle threshold <35); shigellosis was higher in The Gambia (30.8%) than in Mali (9.3%) and Kenya (18.7%). Bloody diarrhea attributed to Shigella was more common in 24- to 59-month-old children (50.1%) than 0- to 11-month-old infants (39.5%). The Shigella flexneri serogroup predominated among cases (67.6% of isolates), followed by Shigella sonnei (18.2%), Shigella boydii (11.8%), and Shigella dysenteriae (2.3%). The most frequent S. flexneri serotypes were 2a (40.6%), 1b (18.8%), 6 (17.5%), 3a (9.0%), and 4a (5.1%). Drug-specific resistance among 353 (98.3%) Shigella cases with AMR data was as follows: trimethoprim-sulfamethoxazole (94.9%), ampicillin (48.4%), nalidixic acid (1.7%), ceftriaxone (0.3%), azithromycin (0.3%), and ciprofloxacin (0.0%).
Conclusions
A high prevalence of shigellosis continues in sub-Saharan Africa. Strains are highly resistant to commonly used antibiotics while remaining susceptible to ciprofloxacin, ceftriaxone, and azithromycin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland.
- Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.
- Medical Research Council Unit, The Gambia at the London School of Hygiene and Tropical Medicine, The Gambia, Banjul.
- Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland.
- Center for Global Health Research, Kenya Medical Research Institute, Kenya, Kisumu.
- Centre pour le Développement des Vaccins du Mali, Mali, Bamako.
Förderung
- Bill & Melinda Gates Foundation
Zitieren
APA
Kasumba, I. N., Badji, H., Powell, H., Hossain, M. J., Omore, R., Sow, S. O., Verani, J. R., Platts-Mills, J. A., Widdowson, M. A., Zaman, S. M. A., Jones, J., Sen, S., Permala-Booth, J., Nasrin, S., Roose, A., Nasrin, D., Ochieng, J. B., Juma, J., Doh, S., …, & Tennant, S. M. (2023). Shigella in Africa: New Insights From the Vaccine Impact on Diarrhea in Africa (VIDA) Study. Clinical Infectious Diseases, 76(Supplement_1), S66-S76. https://doi.org/10.1093/cid/ciac969
Vancouver
Kasumba IN, Badji H, Powell H, Hossain MJ, Omore R, Sow SO, et al. Shigella in Africa: New Insights From the Vaccine Impact on Diarrhea in Africa (VIDA) Study. Clinical Infectious Diseases. 2023;76(Supplement_1):S66-S76. doi:10.1093/cid/ciac969
BibTeX
@article{Kasumba2023,
author = {Kasumba, Irene N and Badji, Henry and Powell, Helen and Hossain, M Jahangir and Omore, Richard and Sow, Samba O and Verani, Jennifer R and Platts-Mills, James A and Widdowson, Marc-Alain and Zaman, Syed M A and Jones, Jennifer and Sen, Sunil and Permala-Booth, Jasnehta and Nasrin, Shamima and Roose, Anna and Nasrin, Dilruba and Ochieng, John Benjamin and Juma, Jane and Doh, Sanogo and Jones, Joquina Chiquita M and Antonio, Martin and Awuor, Alex O and Sugerman, Ciara E and Watson, Nora and Focht, Christopher and Liu, Jie and Houpt, Eric and Kotloff, Karen L and Tennant, Sharon M},
title = {Shigella in Africa: New Insights From the Vaccine Impact on Diarrhea in Africa (VIDA) Study},
journal = {Clinical Infectious Diseases},
year = {2023},
volume = {76},
number = {Supplement_1},
pages = {S66--S76},
doi = {10.1093/cid/ciac969}
}
EUVIMED